Back to results

Insights into healthcare and societal costs of subcutaneous injection and intravenous infusion of trastuzumab for HER2 positive breast cancer and rituximab for non-Hodgkin's lymphoma in The Netherlands

Franken M, Kanters T, Uyl- de Groot C. Institute for Medical Technology Assessment

Please Signup/Login to see the full article.